Advertisement
The TT system is designed to simplify stent graft implants by requiringreduced deployment force, providing the physician with increased control overplacement of the stent graft in the aorta. The TT system offers betterflexibility and an improved coating to increase maneuverability through bloodvessels and a three-part valve system to minimize blood loss during themedical procedure. The TT system also provides better visualization during theprocedure and a more ergonomic design.
Advertisement
"The TT system should improve the ease of use and therefore theperformance of our endovascular stent grafts," said Ryan Connelly, Director,Research & Development of LeMaitre Vascular. "Since we acquired our stentgraft product lines in 2005, we have carefully studied what vascular surgeonsneed to successfully deliver and deploy aortic stent grafts. The new TTsystem gives them what they have been asking for, which will enable betterclinical results and improve patients' lives."
The TT system has already been used by physicians in over a dozenprocedures designed to provide the company with pre-launch clinical feedback.
"I was very pleased with the flexibility of the device and its ability tonavigate tortuous vessels," said Thomas Larzon, MD, Director of theEndoVascular Unit at Orebro University Hospital in Sweden. "It took much lessphysical effort to deploy the stent graft, which meant that I could moreprecisely position the stent graft where it would provide the best outcome forthe patient."
"We are pleased to be able to offer a delivery system that we believemeets the high performance standards set by our stent graft products," saidGeorge W. LeMaitre, Chairman and CEO of LeMaitre Vascular. "We believe thatthe prior generation delivery system had discouraged adoption of our stentgrafts. The TT system removes this impediment to growth."
The TT system will initially be available in a limited range of sizes asthe company scales its production, with all sizes expected to become availableby the end of 2008.
LeMaitre Vascular will be hosting its first ever Analyst Day at theMarriott Marquis Hotel in New York City, on Monday, November 19th. Management,along with vascular surgeon customers, will be giving an overview and updateon the Company and its products, including the new TT Tortuous TrackerDelivery System. A live audio webcast of the presentation will be availablevia the Internet at http://www.lemaitre.com/investor and will be available forreplay for 30 days.
The TT Tortuous Tracker Delivery System and the EndoFit and UniFit AorticStent Grafts are not approved for sale in the United States.
About LeMaitre Vascular
LeMaitre Vascular develops, manufactures, and markets medical devices forthe treatment of peripheral vascular disease. The company's principalexecutive offices are located at 63 Second Avenue, Burlington, Massachusetts01803.
Certain statements set forth above that are not clearly historical innature are forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. These statements include, but arenot limited to, the future clinical performance of the TT Tortuous TrackerDelivery System and the impact that the device may have on LeMaitre Vascular'sgrowth. Although LeMaitre Vascular believes that such statements are based onreasonable assumptions within the bounds of its knowledge of its business andoperations, these forward-looking statements are neit
